Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis

BACKGROUND: DESTINY-Breast03 (NCT03529110) was the first global phase III study to assess the antitumor activity of trastuzumab deruxtecan (T-DXd) compared to trastuzumab emtansine (T-DM1) in 2022. However, the balance between efficacy and cost of T-DXd remains unclear. As a result, the present stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Youwen, Liu, Kun, Wang, Min, Wang, Kailing, Zhu, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619174/
https://www.ncbi.nlm.nih.gov/pubmed/36327624
http://dx.doi.org/10.1016/j.breast.2022.10.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619174/
https://www.ncbi.nlm.nih.gov/pubmed/36327624
http://dx.doi.org/10.1016/j.breast.2022.10.010

Ejemplares similares